{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:14:58Z","timestamp":1762503298237,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ctro.2022.08.009","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:43:03Z","timestamp":1660869783000},"page":"19-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world utilisation of brachytherapy boost and patient-reported functional outcomes in men who had external beam radiation therapy for prostate cancer in Australia"],"prefix":"10.1016","volume":"37","author":[{"given":"Wee Loon","family":"Ong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Millar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctro.2022.08.009_b0005","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","article-title":"Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"23","author":"Sathya","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2022.08.009_b0010","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijrobp.2017.05.013","article-title":"Long-term results of a randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"99","author":"Dayes","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2022.08.009_b0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.ctro.2022.08.009_b0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.ctro.2022.08.009_b0025","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9\u201310 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA, J Am Med Assoc"},{"issue":"14","key":"10.1016\/j.ctro.2022.08.009_b0030","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/cncr.28697","article-title":"The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base","volume":"120","author":"Martin","year":"2014","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ctro.2022.08.009_b0035","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.brachy.2016.05.001","article-title":"The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness","volume":"15","author":"Orio","year":"2016","journal-title":"Brachytherapy"},{"issue":"4","key":"10.1016\/j.ctro.2022.08.009_b0040","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.brachy.2017.03.007","article-title":"Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer","volume":"16","author":"Jackson","year":"2017","journal-title":"Brachytherapy"},{"issue":"5","key":"10.1016\/j.ctro.2022.08.009_b0045","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.06.020","article-title":"Brachytherapy boost utilization and survival in unfavorable-risk prostate cancer","volume":"72","author":"Johnson","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ctro.2022.08.009_b0050","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/pcan.2017.15","article-title":"Trends in the use of radiation therapy for stage IIA prostate cancer from 2004 to 2013: a retrospective analysis using the National Cancer Database","volume":"20","author":"Malouff","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.ctro.2022.08.009_b0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.brachy.2013.08.005","article-title":"Declining use of brachytherapy for the treatment of prostate cancer","volume":"13","author":"Mahmood","year":"2014","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.ctro.2022.08.009_b0060","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/1754-9485.12699","article-title":"Under-utilisation of high-dose-rate brachytherapy boost in men with intermediate-high risk prostate cancer treated with external beam radiotherapy","volume":"62","author":"Ong","year":"2018","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ctro.2022.08.009_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00217","article-title":"Phase 2 multicenter study of gantry-based stereotactic radiotherapy boost for intermediate and high risk prostate cancer (PROMETHEUS)","volume":"9","author":"Pryor","year":"2019","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2022.08.009_b0070","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2019.04.006","article-title":"Stereotactic body radiation therapy boost for intermediate-risk prostate cancer: a phase 1 dose-escalation study","volume":"104","author":"Alayed","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctro.2022.08.009_b0075","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2016.07.013","article-title":"Prostate brachytherapy case volumes by academic and nonacademic practices: implications for future residency training","volume":"96","author":"Orio","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.08.009_b0080","doi-asserted-by":"crossref","DOI":"10.1111\/1754-9485.13424","article-title":"Survey of brachytherapy training experience among radiation oncology trainees and fellows in the Royal Australian and New Zealand College of Radiologists (RANZCR)","author":"Ong","year":"2022","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2022.08.009_b0085","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2022.08.009_b0090","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1016\/j.ijrobp.2011.11.040","article-title":"Long-term results of an RTOG Phase II trial (00\u201319) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate","volume":"82","author":"Lawton","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2022.08.009_b0095","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.clon.2013.01.001","article-title":"Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"32","key":"10.1016\/j.ctro.2022.08.009_b0100","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1200\/JCO.18.00606","article-title":"Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association\/American Society for Radiation Oncology\/Society of Urologic Oncology Guideline","volume":"36","author":"Bekelman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2022.08.009_b0105","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bju.12514","article-title":"Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer","volume":"114","author":"Spratt","year":"2014","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ctro.2022.08.009_b0110","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2015.08.019","article-title":"Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy","volume":"117","author":"Sutani","year":"2015","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2022.08.009_b0115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.clon.2014.06.012","article-title":"Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy","volume":"26","author":"Choudhury","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5","key":"10.1016\/j.ctro.2022.08.009_b0120","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ijrobp.2010.04.046","article-title":"Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer","volume":"80","author":"Morton","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2022.08.009_b0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2005.10.003","article-title":"Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer\u2013a phase II study","volume":"78","author":"Pinkawa","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2022.08.009_b0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2020.10.019","article-title":"Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: a national population-based study","volume":"155","author":"Parry","year":"2021","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2022.08.009_b0135","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.ijrobp.2020.11.023","article-title":"Impact of high-dose-rate and low-dose-rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study","volume":"109","author":"Parry","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4 Pt B","key":"10.1016\/j.ctro.2022.08.009_b0140","first-page":"E158","article-title":"The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer","volume":"111","author":"Evans","year":"2013","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ctro.2022.08.009_b0145","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","article-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","volume":"76","author":"Szymanski","year":"2010","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ctro.2022.08.009_b0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ctro.2022.08.009_b0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2020.07.036","article-title":"Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada","volume":"152","author":"Corkum","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2022.08.009_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ctro.2022.08.009_b0165","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.brachy.2016.07.001","article-title":"Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer","volume":"15","author":"Chen","year":"2016","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ctro.2022.08.009_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient-data network meta-analysis from the MARCAP consortium","author":"Kishan","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ctro.2022.08.009_b0175","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.eururo.2014.08.075","article-title":"Defining a standard set of patient-centered outcomes for men with localized prostate cancer","volume":"67","author":"Martin","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ctro.2022.08.009_b0180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1477-7525-8-104","article-title":"Health care providers underestimate symptom intensities of cancer patients: a multicenter European study","volume":"8","author":"Laugsand","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"24","key":"10.1016\/j.ctro.2022.08.009_b0185","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2008.18.6486","article-title":"Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function","volume":"27","author":"Chen","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2022.08.009_b0190","doi-asserted-by":"crossref","first-page":"e2129647","DOI":"10.1001\/jamanetworkopen.2021.29647","article-title":"Evaluation of hypofractionated radiation therapy use and patient-reported outcomes in men with nonmetastatic prostate cancer in Australia and New Zealand","volume":"4","author":"Pryor","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:11:33Z","timestamp":1762503093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630822000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":38,"alternative-id":["S2405630822000714"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2022.08.009","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world utilisation of brachytherapy boost and patient-reported functional outcomes in men who had external beam radiation therapy for prostate cancer in Australia","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2022.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}